IP Library › Granted Patent US 12,527,780
Granted Patent B2
US 12,527,780 · App. 18/463,851 · Granted Jan 20, 2026

Methods of treating ovarian cancer

Inventors: Mary Lynne Hedley (Wilmington, DE); Robert Martell (Wilmington, DE)
Assignee: Tesaro, Inc.
A61K31/454A61K31/4745A61P35/00A61K9/48C12Q1/6886C12Q2600/106C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,527,780
App. No.
18/463,851
Granted
Jan 20, 2026
Kind
B2
Abstract

The present invention provides methods of administering a PARP inhibitor to a cancer patient.

Claims (13)

1 . A method for the maintenance treatment of an adult patient diagnosed with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, the method consisting of administering to said patient niraparib tosylate monohydrate, wherein the patient is HRD negative and wherein the patient has shown a partial or complete response to platinum-based chemotherapy.

2 . The method of claim 1 , wherein the niraparib tosylate monohydrate is administered in a single daily dose.

3 . The method of claim 1 , wherein the niraparib tosylate monohydrate is administered orally.

4 . The method of claim 1 , wherein the niraparib tosylate monohydrate is administered in a dose equivalent to about 200 mg or about 300 mg of niraparib free base.

5 . The method of claim 1 , wherein the administration of niraparib tosylate monohydrate is commenced within 8 weeks of the end of the last cycle of platinum-based chemotherapy.

6 . The method of claim 1 , wherein the patient is diagnosed with advanced epithelial ovarian cancer.

7 . The method of claim 1 , wherein the patient is diagnosed with advanced fallopian tube cancer.

8 . The method of claim 1 , wherein the patient is diagnosed with advanced primary peritoneal cancer.

9 . A method for the maintenance treatment of an adult patient diagnosed with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, the method consisting of administering daily to said patient an oral dose of niraparib tosylate monohydrate equivalent to about 200 mg or about 300 mg of niraparib free base, wherein the patient is HRD negative and wherein the patient has shown a partial or complete response to platinum-based chemotherapy.

10 . The method of claim 9 , wherein the administration of niraparib tosylate monohydrate is commenced within 8 weeks of the end of the last cycle of platinum-based chemotherapy.

11 . The method of claim 9 , wherein the patient is diagnosed with advanced epithelial ovarian cancer.

12 . The method of claim 9 , wherein the patient is diagnosed with advanced fallopian tube cancer.

13 . The method of claim 9 , wherein the patient is diagnosed with advanced primary peritoneal cancer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2023
From: HEDLEY, MARY LYNNE; MARTELL, ROBERT
To: TESARO, INC.
Reel/Frame 065462/0423 →
Continuity (7)
Continuation 17652422 · Feb 24, 2022
Continuation 15986536 · May 22, 2018
Continuation PCTUS2017040039 · Jun 29, 2017
Provisional Application 62470141 · Mar 10, 2017
Provisional Application 62402427 · Sep 30, 2016
Provisional Application 62356461 · Jun 29, 2016
Related Publication 20240058319A1 · Feb 22, 2024
References Cited (400)
US 8071623B2 · Jones et al. · 2011 [cited by applicant]
US 8436185B2 · Foley et al. · 2013 [cited by applicant]
US 9580407B2 · Chung et al. · 2017 [cited by applicant]
US 9738915B2 · Bulger et al. · 2017 [cited by applicant]
US 20090123419A1 · Sherman et al. · 2009 [cited by applicant]
US 20090275619A1 · Boueres et al. · 2009 [cited by applicant]
US 20100009930A1 · Sherman et al. · 2010 [cited by applicant]
US 20100286157A1 · Quigley et al. · 2010 [cited by applicant]
US 20100286203A1 · Foley et al. · 2010 [cited by applicant]
US 20110118217A1 · Gudmundsson et al. · 2011 [cited by applicant]
US 20110201657A1 · Boueres et al. · 2011 [cited by applicant]
US 20120207856A1 · Ajay et al. · 2012 [cited by applicant]
US 20120214998A1 · Bierlmaier et al. · 2012 [cited by applicant]
US 20130310424A1 · Surber · 2013 [cited by applicant]
US 20140363521A1 · Abkevich · 2014 [cited by applicant]
US 20150110869A1 · Philip et al. · 2015 [cited by applicant]
US 20150344968A1 · Johnson · 2015 [cited by applicant]
US 20160160294A1 · Wilcoxen et al. · 2016 [cited by applicant]
US 20170000885A1 · Rhee et al. · 2017 [cited by applicant]
US 20170029428A1 · Blatter et al. · 2017 [cited by applicant]
US 20170137403A1 · Chung et al. · 2017 [cited by applicant]
US 20170335359A1 · Bulger et al. · 2017 [cited by applicant]
US 20180311224A1 · Hedley et al. · 2018 [cited by applicant]
US 20190060285A1 · Proia · 2019 [cited by applicant]
US 20210106574A1 · Feng et al. · 2021 [cited by applicant]
US 20220175751A1 · Hedley et al. · 2022 [cited by applicant]
US 20220175752A1 · Hedley et al. · 2022 [cited by applicant]
US 20220395439A1 · Hedley et al. · 2022 [cited by applicant]
CA 2893280 · 2014 [cited by applicant]
CN 105384695 · 2016 [cited by applicant]
CN 105960415 · 2016 [cited by applicant]
CN 106132439 · 2016 [cited by applicant]
CN 106432055 · 2017 [cited by applicant]
CN 106496187 · 2017 [cited by applicant]
JP 2011506252 · 2011 [cited by applicant]
JP 2011509252 · 2011 [cited by applicant]
JP 2011509253 · 2011 [cited by applicant]
JP 2017504623 · 2017 [cited by applicant]
JP 2017509631 · 2017 [cited by applicant]
JP 2017527799 · 2017 [cited by applicant]
WO WO2007113596 · 2007 [cited by applicant]
WO WO2008084261 · 2008 [cited by applicant]
WO WO2009087381 · 2009 [cited by applicant]
WO WO2011058367 · 2011 [cited by applicant]
WO WO2011153383 · 2011 [cited by applicant]
WO WO2011160063 · 2011 [cited by applicant]
WO WO2012027224 · 2012 [cited by applicant]
WO WO2013182645 · 2013 [cited by applicant]
WO WO2014052550 · 2014 [cited by applicant]
WO WO2014088983 · 2014 [cited by applicant]
WO WO2014088984 · 2014 [cited by applicant]
WO WO2014138101 · 2014 [cited by applicant]
WO WO2014179664 · 2014 [cited by applicant]
WO WO2015108986 · 2015 [cited by applicant]
WO WO2015119930 · 2015 [cited by applicant]
WO WO2015153514 · 2015 [cited by applicant]
WO WO2015184145 · 2015 [cited by applicant]
WO WO2016094391 · 2016 [cited by applicant]
WO WO2016200835 · 2016 [cited by applicant]
WO WO2017075091 · 2017 [cited by applicant]
WO WO2017139694 · 2017 [cited by applicant]
WO WO2018005818 · 2018 [cited by applicant]
WO WO2018023017 · 2018 [cited by applicant]
WO WO2018183349 · 2018 [cited by applicant]
WO WO2018183354 · 2018 [cited by applicant]
WO WO2018200517 · 2018 [cited by applicant]
WO WO2018201096 · 2018 [cited by applicant]
WO WO2019005762 · 2019 [cited by applicant]
WO WO2019067634 · 2019 [cited by applicant]
WO WO2019123207 · 2019 [cited by applicant]
WO WO2019133697 · 2019 [cited by applicant]
WO WO2021011609 · 2021 [cited by applicant]
[No Author Listed], “Assessment report—Zejula,” European Medicines Agency, Sep. 17, 2017, 122 pages. [cited by applicant]
[No Author Listed], “Dear Health Care Provider Letter (Niraparib)—Important Prescribing Information,” GSK, Nov. 2022, 3 pages. [cited by applicant]
[No Author Listed], “Medical Review 206162Orig1s000 (Olaparib),” Center for Drug Evaluation and Research, 2014, 131 pages. [cited by applicant]
Adams, “Tesaro's PARP ovarian cancer drug hits PhIII goal; prepares to file,” Jun. 29, 2016, retrieved from URL <https://www.fiercebiotech.com/biotech/tesaro-s-parp-ovarian-cancer-drug-hits-phiii-goal-prepares-to-file>,… [cited by applicant]
Akay et al., “An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions,” Oncology and Therapy, Dec. 2021, 9:347-364. [cited by applicant]
Al Hilli et al., “Abstract PR05: In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer,” Clin Cancer Res., 2013, 19 (19_Supplement), 5 p… [cited by applicant]
ASCOpost.com [online], “NOVA: Final Analysis Confirms No Significant Overall Survival Benefit for Maintenance Niraparib in Recurrent Ovarian Cancer,” May 25, 2024, retrieved from URL <https://ascopost.com/issues/may-25-… [cited by applicant]
ClinicalTrials.gov [online], “NCT01847274—A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer,” version 32, May 11, 2016, retrieved from URL <https://clinicaltrials.gov/s… [cited by applicant]
ClinicalTrials.gov [online], “Protocol of clinical trial NCT01847274—A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer,” Dec. 23, 2014, retrieved from URL <https://clin… [cited by applicant]
ClinicalTrials.gov [online], “Protocol of clinical trial NCT01847274—A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer,” May 11, 2016, retrieved from URL <https://clini… [cited by applicant]
Drew, “The development of PARP inhibitors in ovarian cancer: from bench to bedside,” Br. J. Cancer 2015, 113: S3-S9. [cited by applicant]
Globenewswire.com [online], “TESARO's Niraparib Significantly Improved Progression—Free Survival for Patients With Ovarian Cancer in Both Cohorts of the Phase 3 NOVA Trial,” Jun. 29, 2016, retrieved from URL <https://ww… [cited by applicant]
How et al., “Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer,” Cancers (Basel), Feb. 24, 2021, 13(946):1-17. [cited by applicant]
Kaye, “Progress in the treatment of ovarian cancer—lessons from homologous recombination deficiency—the first 10 years,” SB Annals of Oncology, Apr. 2016, 27(Supplement 1):i1-i3. [cited by applicant]
Konstantinopoulos et al., “BRCA status in epithelial ovarian cancer: implications for management and future clinical trial design,” Clinical Investigation, 2013, 3(8):777-790. [cited by applicant]
Mirza et al., “Abstract 941TP: ENGOT-OV16/NOVA: A Phase 3 Randomized Double-Blind Trial of Maintenance with PARP-Inhibitor Niraparib versus Placebo in Patients with Platinum-Sensitive Ovarian Cancer,” Annals of Oncology… [cited by applicant]
Myriad.com [online], “myChoice HRD(TM) Test Identifies Breast Cancer Patients Likely to Respond to Platinum-Containing Therapies,” Press Release Myriad genetics Press Release, Dec. 10, 2015, retrieved from URL<https://i… [cited by applicant]
Ngoi et al., “The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?,” ESMO Open, 2021, 6(3):1-12. [cited by applicant]
OncLive.com [online], “Role of PARP Inhibitors in Advanced Ovarian Cancer,” May 30, 2023, retrieved from URL <https://www.onclive.com/view/role-of-parp-inhibitors-in-advanced-ovarian-cancer>, 7 pages. [cited by applicant]
OncLive.com [online], “Treatment of HRD-Negative Cancer,” Oct. 24, 2019, retrieved from URL <https://www.onclive.com/view/treatment-of-hrd-negative-ovarian-cancer>, 5 pages. [cited by applicant]
Sehouli et al., “PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives,” Geburtshilfe Frauenheilkd, Feb. 2016, 76(2):164-169. [cited by applicant]
Stronach et al., “Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNEI Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy,” Mol Cancer Res, 2018, 16(7):… [cited by applicant]
Symeonides et al., “Ovarian cancer molecular stratification and tumor heterogeneity: a necessity and a challenge,” Frontiers in Oncology, Oct. 2015, 5(229):1-5. [cited by applicant]
Telli, “PARP Inhibitors in cancer: moving beyond BRCA,” The Lancet Oncology, 2011, 12:827-828. [cited by applicant]
Tesarobio.com [online], “NIRAPARIB,” available on or before Jun. 22, 2016, via internet archive: Wayback Machine, retrieved from URL <https://web.archive.org/web/20160622232504/http:/www.tesarobio.com/niraparib>, 4 page… [cited by applicant]
Turner et al., “A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor,” EMBO Journal, Apr. 2008, 27:1368-1377. [cited by applicant]
U.S. Food and Drug Administration, “ZEJULA (niraparib) capsules: Highlights of Prescribing Information,” Dec. 2022, 32 pages. [cited by applicant]
European Search Report in European Application No. 23211450.4, dated Feb. 15, 2024, 11 pages. [cited by applicant]
Chemicalbook.com [online], “CAS No. 1613220-15-7—Niraparib tosylate,” Sep. 18, 2016, retrieved on Nov. 24, 2021, retrieved from URL: <https://www.chemicalbook.com/ChemicalProductProperty_EN_CB53336280.htm>, 2 pages. [cited by applicant]
Feng et al., “Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma,” Journal of Ovarian Research, Mar. 15, 2023, 16(53)… [cited by applicant]
Jackson et al., “Personalised Cancer Medicine,” Int. J. Cancer, Jul. 15, 2015, 137(2):262-266. [cited by applicant]
Michels et al., “Predictive biomarkers for cancer therapy with PARP inhibitors,” Oncogene, Jul. 24, 2014, 33(30:)3894-3907. [cited by applicant]
SRL-group.co.jp, “myChoice Diagnostic System,” Jan. 4, 2021, retrieved on Jun. 3, 2024, retrieved from URL: <https://www.srl-group.co.jp/assets/pdf/news/testing/2021-01.pdf>, 4 pages (with Machine Translation). [cited by applicant]
[No. author listed] “Integrated genomic analyses of ovarian carcinoma,” Nature, 2011, 474:609-615. [cited by applicant]
Berge et al., “Pharmaceutical Salts,” J Pharmaceutical Sciences, 1977, 66(1):1-19. [cited by applicant]
Bois et al., “A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumors,” Br. J Cancer, 2006, 94(1):79-84. [cited by applicant]
Brown et al, “Combining DNA damaging therapeutics with immunotherapy: more haste, less speed,” British Journal of Cancer, Nov. 9, 2017, 118 (3):312-324. [cited by applicant]
Chemicalbook.com, “Niraparib tosylate,” retrieved Nov. 24, 2021, from URL <https://www.chemicalbook.com/ChemicalProductProperty EN_CB53336280.htm>, 2 pages. [cited by applicant]
ClinicalTrials.gov [online], “A Maintenance Study with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer,” dated May 6, 2013, retrieved on Nov. 24, 2021, from URL <https://clinicaltrials.gov/ct… [cited by applicant]
ClinicalTrials.gov [online], “A Phase I/II Study of MEDI4736 in Combination with Olaparib in Patients with Advanced Solid Tumors. (Mediola),” U.S. National Library of Medicine, Apr. 12, 2016, retrieved on Jul. 6, 2022, … [cited by applicant]
ClinicalTrials.gov [online], “NCT02657889: Niraparib in Combination with Pembrolizumab in Patients with Triple-negative Breast Cancer or Ovarian Cancer,” Oct. 27, 2021, retrieved on Nov. 28, 2022, retrieved from URL: <h… [cited by applicant]
Dann et al., “BRCA 1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer,” Gynecol. Oncol., 2012, 125(3):677-682. [cited by applicant]
Hamanishi et al., “Immune Checkpoint Inhibition in Ovarian Cancer,” International Immunology, Apr. 7, 2016, 28(7): 339-348. [cited by applicant]
Hamanishi et al., “PD1/PDL1 Blockade in Cancer Treatment: Perspectives and Issues,” Int. J. Clin. Oncol., Feb. 22, 2016, 21: 462-473. [cited by applicant]
Hennessy et al., “Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit from Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer,” J Clin Oncol. 2010, 28(22):3570-3576. [cited by applicant]
Herzog et al., “Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper,” Gynecol Oncol. 2014; 132(1):8-17. [cited by applicant]
Jiao et al., “PARP inhibitor upregulates PD-L1 expression and enhances cancer- associated immunosuppression,” Clinical Cancer Research, Feb. 2017, 23(14):3711-3720. [cited by applicant]
Ledermann et al., “Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer,” New England Journal of Medicine, 2012, 366:1382-92. [cited by applicant]
Merriam-Webster.com [online], “Deficient,” Merriam-Webster, 2022, 7 pages. [cited by applicant]
Ohmoto et al., “Current status of poly(ADP-ribose) polymerase inhibitors and future directions,” Onco. Targets Ther., Oct. 26, 2017, 10:5195-5208. [cited by applicant]
PCT Invitation to Pay Additional Fees in International Application No. PCT/US2018/067653, dated Apr. 2, 2019, 18 pages. [cited by applicant]
Zhang et al., “A Genomic Instability Score in Discriminating Nonequivalent Outcomes of BRCA1/2 Mutations and in Predicting Outcomes of Ovarian Cancer Treated with Platinum-Based Chemotherapy,” Public Library of Science,… [cited by applicant]
Zhu et al., “Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer,” Journal of Gynecologic Oncology, Sep. 2017, 28(5):e64, 19 pages. [cited by applicant]
U.S. Appl. No. 16/612,363, filed Nov. 8, 2019, Bobilev et al. [cited by applicant]
Abkevich et al., “Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer”, Br J Cancer. 2012, 107(10): 1776-1782. [cited by applicant]
Aghajanian et al., “OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal… [cited by applicant]
Alhilli et al., “In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma,” Gynecologic Oncology, 2016, 143: 379-388. [cited by applicant]
Ali et al., “A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient,” Case Reports in Oncology, Jan.-Apr. 2… [cited by applicant]
American Cancer Society, “Ovarian Cancer, 2016”, retrieved on May 13, 2019, retrieved from URL <http://www.cancer.org/cancer/ovariancancer/index>. [cited by applicant]
American Cancer Society, Inc. Cancer Facts & Figures, p. 18, (2016), [online] (retrieved on May 19, 2019). Retrieved from the Internet: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/… [cited by applicant]
Anderson et al., “Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 expression in vitro and in vivo,” Nuclear Medicine and Biology, vol. 43 (12): 752-758, Dec. 2016. [cited by applicant]
Anonymous, “Niraparib Slows Ovarian Cancer Progression”, Cancer Discovery, 6(12): OF2, (2016). [cited by applicant]
Antoniou et al., “Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction”, Cancer Res., 2010; 70(23): 9742-9754. [cited by applicant]
Audeh et al., “Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial”, Lancet, 2010; 376(9737): 245-251. [cited by applicant]
Audeh MW, “Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition”, Pharmgenomics Pers Med, Oct. 2014, 7: 307-316. [cited by applicant]
Baciarello et al., “Advancing therapies in metastatic castration-resistant prostate cancer”, Expert Opinion on Pharmacotherapy, Nov. 2, 2018, 19 (16):1797-180. [cited by applicant]
Bai et al., “Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy”, Journal of Cellular and Molecular Medicine, vol. 20 (4): 581-593, Apr. 2016. [cited by applicant]
Bakir et al., “The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future,” British Medical Bulletin, 2014, 13 pages, 112:57-69; doi: 10.1093/bmb/ldu034. [cited by applicant]
Bast et al., “Prevention and early detection of ovarian cancer: mission impossible?”, Recent Results Cancer Res., 2007; 174:91-100. [cited by applicant]
Beaumont et al., “Validation of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) Symptom Index (FOSI) in a Phase II Clinical Trial of Pertuzumab in Patients with Advanced Ovarian Cancer”, Journal of Clinical… [cited by applicant]
Berek et al., “Safety and dose modification for patients receiving niraparib,” Ann. Oncol., 29(8):1784-1792, (2018). [cited by applicant]
Birkbak et al., “Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents”, Cancer Discov. 2012; 2(4): 366-375. [cited by applicant]
Birrer “Ovarian cancer: targeting the untargetable”, Am Soc Clin Oncol Educ Book. 2014: 13-15. [cited by applicant]
Bookman et al., “Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup,” J Clin Oncol., 2009, 27(9):1419-1425. [cited by applicant]
Boyer, “Medical Oncology: in Cancer A Comprehensive Clinical Guide,” Harwood Academic Publishers, 2005; Chapter 6, 14 pages. [cited by applicant]
Brasseur et al., “Chemoresistance and targeted therapies in ovarian and endometrial cancers”, Oncotarget, vol. 8 (3): 4008-4042, Jan. 17, 2017. [cited by applicant]
Bridges et al., “Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells”, Oncotarget, Jul. 15, 2014; 5(13):5076-86. [cited by applicant]
Bryant et al., “Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase”, Letters to Nature, Apr. 2005, 434: 913-917. [cited by applicant]
Bryant et al., “Synthetic Lethality with Homologous Recombination Repair Defects”, PARP Inhibitors for Cancer Therapy (Cancer Drug Discovery and Development), Chapter 13, 315-344 (2015). [cited by applicant]
Caffo et al., “Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?”, Frontiers in Cell and Developmental Biology, Sep. 5, 2018, 6(71):1-5. [cited by applicant]
Cancer Genome Atlas Research Network, “Integrated genomic analyses of ovarian carcinoma”, Nature, 2011; 474(7353):609-615. [cited by applicant]
Carey et al., “Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer”, Cancer Res., Feb. 1, 2018 ;78(3):742-57. [cited by applicant]
Caron, “Current place of oncogenetics in the management of ovarian cancer”, Gynecologie Obstetrique & Fertilite, vol. 43 (5): 335-337, May 2015 (machine translation provided). [cited by applicant]
Caruso et al., “Niraparib in ovarian cancer: results to date and clinical potential”, Therapeutic Advances in Medical Oncology, 9(9): 579-588 (2017). [cited by applicant]
CAS No. 1613220-15-7, “Niraparib Tosylate Monohydrate,” SimSon Pharma Limited, retrieved on Aug. 3, 2022, retrieved from URL<https://www.simsonpharma.com/product/niraparib-tosylate-monohydrate>, 2 pages. [cited by applicant]
Chang et al., “Enhanced Anti-Tumor Effects of Selinexor and Niraparib in Preclinical Models of Ovarian Cancer”, (Abstract 5826). Presented at AACR 2018 (Poster). [cited by applicant]
Chao et al., “Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and Parp”, Molecular Cancer Research, vol. 12 (12): 1755-1766, Dec. 2014. [cited by applicant]
Chase et al.; “Profile of Olaparib in the treatment of advanced ovarian cancer,” Int. J. Women's Health, 6(8): 125-129 (2016). [cited by applicant]
Chen et al., “BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway”, Cancer Res., 1999; 59(7 Suppl): 1752s-1 756s. [cited by applicant]
Chen et al., “The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others”, Biomedicine & Pharmacotherapy, vol. 99: 552-560, Mar. 2018. [cited by applicant]
Christenson et al., “PARP inhibitors for homologous recombination-deficient prostate cancer”, Expert Opinion On Emerging Drugs, vol. 23 (2): 123-133, 2018. [cited by applicant]
Chuang-Stein, “Some issues concerning the normalization of laboratory data based on reference ranges”, Drug Information Journal, 2001; 35:153-156. [cited by applicant]
ClinicalTrials.gov [online], “A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA),” last updated Jul. 27, 2022 , retrieved from the internet Sep. 13, 2022, retri… [cited by applicant]
Clinicaltrials.gov [online], “Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination with Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovari… [cited by applicant]
Coleman et al., “A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients wh… [cited by applicant]
Company B-MS, “TAXOL® (paclitaxel) Injection” Package Insert. 2011; https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s0491bl.pdf, Accessed May 17, 2016, 53 pages. [cited by applicant]
Conner-Spady et al., “Responsiveness of the EuroQol in breast cancer patients undergoing high dose chemotherapy”, Qual Life Res., 2001; 10(6):479-486. [cited by applicant]
Cook et al., “Early phase clinical trials to identify optimal dosing and safety”, Molecular Oncology, 9(5): 997-1007 (2015). [cited by applicant]
Dangi-Garimella, “New PARP Inhibitor, Niraparib, Approved as Maintenance Therapy for Ovarian and Other Cancers,” AJMC, Mar. 28, 2017, retrieved on Oct. 26, 2023, retrieved from URL <https://www.ajmc.com/view/new-parp-in… [cited by applicant]
Davies et al., “Top 40 Drugs in the Pipeline”, A Supplement to C&EN, 1-33, (2016). [cited by applicant]
Deas et al., “Preclinical evaluation of the PARP inhibitor niraparib and cytotoxic chemotherapy alone or in combination in a panel of 25 triple-negative breast cancer POX models: relevance of BRCA mutations, HRD status … [cited by applicant]
Del Campo JM et al., “The Successful Phase 3 Niraparib ENGOT-OV16/NOVA Trial Included a Substantial Number of Patients with Platinum Resistant Ovarian Cancer”, ASCO 2017 (Poster). [cited by applicant]
Del Rivero et al., “PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies”, Oncology-New York, vol. 31 (4): 265-273, Apr. 2017. [cited by applicant]
Doubeni et al., “Diagnosis and Management of Ovarian Cancer,” American Family Physician, Jun. 1, 2016, 93(11):938-944. [cited by applicant]
Drew et al., “Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and brea… [cited by applicant]
Du Bois et al., “2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004),” Ann Oncol., 20… [cited by applicant]
Elston, “On Fisher's Method of Combining p-Values”, Biometrical Journal., 1991; 33(3):339-345. [cited by applicant]
Engert et al., “PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide- Induced Apoptosis via the Mitochondrial Pathway”, Mol Cancer Ther., Dec. 2015; 14(12):2818-30. [cited by applicant]
Erzog et al., “Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper”, Gynecol Oncol., 2014; 132(1):8-17. [cited by applicant]
Essel et al., “Niraparib for the treatment of ovarian cancer”, Expert Review of Anticancer Therapy, 18(8): 727-733 (2018). [cited by applicant]
Etheir et al., “The role of niraparib for the treatment of ovarian cancer”, Future Oncology, vol. 14 (25): 2565-2577, Oct. 2018. [cited by applicant]
European Search Report dated Feb. 14, 2020 for EP Application No. 17821262.7. [cited by applicant]
Ex Parte Liu, APPEAL 2018-000869, 2018 WL 3492109 (Jul. 3, 2018). [cited by applicant]
Ex Parte Pu, Appeal 2017-003775, 2018 WL 3425476 at (Jun. 25, 2018). [cited by applicant]
Extended European Search Report and Written Opinion mailed on Feb. 11, 2021, for EP Patent Application No. 18797986.9, 16 pages. [cited by applicant]
Ezzalfani et al., “The role of the expansion cohort in phase I trials in oncology: Guidelines of the phase I Hub”, Bulletin Du Cancer, vol. 102 (1): 73-82, Jan. 2015 (English language abstract). [cited by applicant]
Fabbro et al., “Safety and efficacy of niraparib in elderly patients (Pts) with recurrent ovarian cancer (OC)”, Presented at ESMO; Sep. 8-12, 2017; Madrid, Spain. 934PD. [cited by applicant]
Fang, “Development of Synthetic Lethality Anticancer Therapeutics”, Journal of Medicinal Chemistry, vol. 57 (19): 7859-7873, Oct. 9, 2014. [cited by applicant]
Farmer et al., “Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy”, Nature, 434: 917-921 (2005). [cited by applicant]
FDA Briefing Document: Oncologic Drugs Advisory Committee Meeting, Jun. 25, 2014. [cited by applicant]
Feng et al., “Molecular Pathways: Targeting ETS Gene Fusions in Cancer”, Clinical Cancer Research, vol. 20 (17): 4442-4448, Sep. 1, 2014. [cited by applicant]
Ferraldeschi et al., “Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects”, Oncogene, vol. 34 (14): 1745-1757, Apr. 2, 2015. [cited by applicant]
Ferrara et al., “The development of P ARP as a successful target for cancer therapy”, Expert Review of Anticancer Therapy, vol. 18 (2): 161-175, 2018. [cited by applicant]
Ferrario et al., “Advances in the approach to novel drug clinical development for breast cancer”, Expert Opinion on Drug Discovery, vol. 9 (6): 647-668, Jun. 2014. [cited by applicant]
Ferrel et al., “Psychological well being and quality of life in ovarian cancer survivors”, Cancer. 2003; 98(5): 1061-1071. [cited by applicant]
Fisher Met al., “Cost-effectiveness of niraparib versus routine surveillance, olaparib and rucaparib for the maintenance treatment of adult patients with ovarian cancer in the United States”, Accepted at ASCO 2018 (Post… [cited by applicant]
Foley et al., “Recurrent epithelial ovarian cancer: an update on treatment,” Oncology (Williston Park), Apr. 2013, 27(4):288-294. [cited by applicant]
Fong et al., “Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers”, N Engl J Med., 2009; 361(2): 123-134. [cited by applicant]
Fotopoulou, “Limitations to the use of carboplatin-based therapy in advanced ovarian cancer”, EJC Suppl. 2014; 12(2): 13-16. [cited by applicant]
Fox et al., “The sooner the better: Genetic testing following ovarian cancer diagnosis”, Gynecologic Oncology, vol. 137 (3): 423-429, Jun. 2015. [cited by applicant]
Franzese et al., “PARP inhibitors in ovarian cancer”, Cancer Treatment Reviews, vol. 73: Feb. 1-9, 2019. [cited by applicant]
Freidlin et al., “Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients”, Clin Cancer Res., 2005; 11(21): 7872-7878. [cited by applicant]
Frey et al., “Targeting DNA repair: poly (ADP-ribose) polymerase inhibitors”, Translational Cancer Research, vol. 4 (1): 84-96, Feb. 2015. [cited by applicant]
Gadi et al., “Practical Approach to Triple-Negative Breast Cancer”, Journal of Oncology Practice, vol. 13 (5): 293-300 May 2017. [cited by applicant]
Garcia et al., “A Comprehensive Approach to the Identification and Management of the BRCA Patient”, OBSTETRICAL & Gynecological Survey, vol. 70 (2): 131-143, Feb. 2015. [cited by applicant]
Gavande et al., “DNA repair targeted therapy: The past or future of cancer treatment?”, PHARMACOLOGY & THERAPEUTICS, vol. 160: 65-83, Apr. 2016. [cited by applicant]
Geenen et al., “PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer”, Clinical Pharmacokinetics, vol. 57 (4): 427-437, Apr. 2018. [cited by applicant]
Gelmon et al., “Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study”, Lancet Oncol.… [cited by applicant]
Genther-Williams et al., “Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status”, Cancer Cell Int., Feb. 4, 2015; 15(1):14. [cited by applicant]
George et al., “Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer”, Nature Reviews Clinical Oncology, 14(5): 284-296 (2017). [cited by applicant]
Goff et al., “Frequency of symptoms of ovarian cancer in women presenting to primary care clinics”, JAMA, 2004; 291(22): 2705-2712. [cited by applicant]
Gonzalez et al., “A randomized, double-blind phase 3 trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy”, ASCO 2016 (Poster). [cited by applicant]
Gonzalez et al., “A randomized, double-blind phase 3 trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy”, SGO 2017 (Poster). [cited by applicant]
Gonzalez et al., “A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy”, Presented at ESMO… [cited by applicant]
Gonzalez et al., “The ENGOT-OV26/PRIMA phase 3 trial: Niraparib maintenance treatment in patients with advanced ovarian cancer who responded to front-line platinum-based therapy”, ESGO 2017 (e-poster). [cited by applicant]
Gonzalez-Martin et al., “Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer,” The New England Journal of Medicine, 2019, 381(25): 2391-2402. [cited by applicant]
Goodman, “'Breakthrough' in Recurrent Ovarian Cancer: Niraparib Extends Progression-Free Survival in Platinum-Sensitive Disease”, HSP News Service, LLC., Nov. 2016, 6 pages. [cited by applicant]
Gras, “Niraparib hydrochloride. Poly [ADP-ribose] polymerase (PARP) inhibitor, Oncolytic”, Drugs of the Future, vol. 38 (10): 679-685, Oct. 2013. [cited by applicant]
Guy Jet al., “Cost-effectiveness of niraparib versus routine surveillance and olaparib for the maintenance treatment of adult patients with ovarian cancer in the United States”, Accepted at ISPOR 2018 (Poster). [cited by applicant]
Haluska Pet al., “Homologous recombination deficiency (HRD) score and niraparib efficacy in high grade ovarian cancer”, Emergency Nurses Association 2014. (Oral Presentation). [cited by applicant]
Hamilton et al., “Emotional Distress Following Genetic Testing for Hereditary Breast and Ovarian Cancer: A Meta-Analytic Review”, Health Psychol., 28(4): 510-518 (2009). [cited by applicant]
Hanker et al., “The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy”, Ann Oncol., 2012; 23(10):2605-2612. [cited by applicant]
Harrow Bet al., “Disease burden during the “watchful waiting” period in patients with recurrent ovarian cancer”, Presented at ESMO; Sep. 8-12, 2017; Madrid, Spain. 962P. [cited by applicant]
Harrow Bet al., “Disease Burden During the 'Watchful Waiting' Period in Women with Recurrent Ovarian Cancer in Germany”, EU ISPOR 2017 (Poster). [cited by applicant]
Havrilesky et al., “Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment”, Gynecol Oncol., 2009; 113(2): 216-220. [cited by applicant]
Havrilesky et al., “Patient preferences in advanced or recurrent ovarian cancer”, Cancer, 2014; 120(23):3651-3659. [cited by applicant]
Havrilesky et al., “Quality of life in ICON7: need for patients' perspectives”, Lancet Oncol., 2013; 14(3): 183-185. [cited by applicant]
Heo et al., “Niraparib: A Review in Ovarian Cancer”, Targeted Oncology, Aug. 2018, 13(4):533-539. [cited by applicant]
Herzog et al., “SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm”, Gynecol Oncol., 2014;135(1):3-7. [cited by applicant]
Hill et al., “Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids”, Cancer Discovery, vol. 8 (11): 1404-1421 Nov. 2018. [cited by applicant]
Hopkins et al., “PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow”, Molecular Cancer Research, vol. 17 (2): 409-419 Feb. 2019. [cited by applicant]
Hopkins TA et al., “Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors”, Mol Cancer Res., Jul. 27, 2015. [cited by applicant]
Hoskins, “Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature”, Clinical Oncology, vol. 30 (8): 472-483 Sp. Iss. SI,… [cited by applicant]
http://ir.tesarobio.com/news-releases/news-release-details/tesaro-and-myriad-announce-companion-diagnostics-collaboration. [cited by applicant]
http://ir.tesarobio.com/news-releases/news-release-details/tesaro-announces-us-fda-approval-zejulatm-niraparib-women. [cited by applicant]
http://ir.tesarobio.com/news-releases/news-release-details/tesaros-niraparib-significantly-improved-progression-free. [cited by applicant]
http://www.ascopost.com/issues/january-25-2017/parp-inhibitor-niraparib-yields-unprecedented-results-in-ovarian-cancer-in-phase-iii-trial/?utm_source=TrendMD&utm_medium=cpc&utm_campaign=The_ASCO_Post TrendMD 0. [cited by applicant]
http://www.ascopost.com/issues/november-25-2016/breathrough-in-recurrent-ovarian-cancer-niraparib-extends-progression-free-survival-in-platinum-sensitive-disease/. [cited by applicant]
http://www.ascopost.com/issues/november-25-2016/expert-point-of-view-sandro-pignata-md/. [cited by applicant]
http://www.egdutton2.com/research/progress/snapshots/ovarian.html. [cited by applicant]
http://www.egdutton2.com/types/ovarian/hp/ovarian-epithelial-treatment-pdq.html. [cited by applicant]
http://www.pharmafile.com/news/188925/fda-rejects-olaparib. [cited by applicant]
http://www.pmlive.com/pharma_news/tesaros_niraparib_threatens_lynparza_after_ac ing ovarian cancer trial 1160149. [cited by applicant]
https://blogs.shu.edu/cancer/2014/06/26/parp-inhibitor-rejected-by-fda-advisory-committee/. [cited by applicant]
https://clinicaltrials.gov/ct2/show/NCT02655016?term=niraparib&recrs=d&rank=7. [cited by applicant]
https://ir.clovisoncology.com/investors-and-news/news-releases/press-release-details/2016/Clovis-Oncology-Announces-FDA-Accelerated-Approval-of-RUBRACA-rucaparib-for-the-Monotherapy-Treatment-of-Advanced-Ovarian-Cancer-… [cited by applicant]
https://myriad.com/patients-families/genetic-testing-101/genetic-testing-faqs/. [cited by applicant]
https://ocrahope.org/patients/about-ovarian-cancer/recurrence/. [cited by applicant]
https://seekingalpha.com/article/4011207-tesaro-enjoys-ta-dah-moment. [cited by applicant]
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/20844?Orig1s000Ltr.pdf. [cited by applicant]
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208447Orig1s000Approv.pdf, 11 pages. [cited by applicant]
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208447Orig1s000ChemR.pdf, 56 pages. [cited by applicant]
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208447Orig1s000OtherR.pdf. [cited by applicant]
https://www.astrazeneca.com/media-centre/press-releases/2011/AstraZeneca-updates-on-olaparib-and-TC-5214-development-programmes-20122010.html#. [cited by applicant]
https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-olaparib-clinical-programme-brca-mutated-ovarian-cancer-treatment-04092013.html#. [cited by applicant]
https://www.astrazeneca.com/media-centre/press-releases/2016/lynparza-phase-iii-solo-2-trial-shows-significant-progression-free-survival-benefit-261020161.html#. [cited by applicant]
https://www.astrazeneca.com/media-centre/press-releases/2018/solo-1-phase-III-trial-demonstrates-lynparza-maintenance-therapy-cut-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advan… [cited by applicant]
https://www.astrazeneca-us.com/media/press-releases/2014/lynparza-approved-by-the-us-fda-20141219.html#! [cited by applicant]
https://www.cancer.gov/ty12es/ovarian ?redirect=true and. [cited by applicant]
https://www.cancer.gov/types/ovarian/hp/ovarian-epithelial-treatment-pdq#section/. [cited by applicant]
https://www.esmo.org/Conferences/Past-Conferences/ESMO-2016-Congress/Press-Media/Niraparib-Significantly-Improves-Outcome-of-Ovarian-Cancer-Patients-in-Landmark-Trial. [cited by applicant]
https://www.fool.com/investing/2016/06/29/shares-of-tesaro-inc-have-more-than-doubled-today.aspx. [cited by applicant]
https://www.mdedge.com/oncologypractice/article/115513/gynecologic-cancer/parp-inhibitor-prolongs-pfs-ovarian-cancer. [cited by applicant]
https://www.medscape.com/viewarticle/870021. [cited by applicant]
https://www.onclive.com/web-exclusives/fda-approves-niraparib-for-ovarian-cancer. [cited by applicant]
https://www.statnews.com/2016/06/30/ovarian-cancer-new-drugs/. [cited by applicant]
https://www.streetinsider.com/Analyst+Comments/TESAR0+%28TSR0%29+Phase+3+Niraparib+Results+a+Grand+Slam+-+Mizuho/11784621.htm. [cited by applicant]
https://xconomy.com/boston/2017/03/27/tesaros-ovarian-cancer-drug-gets-fda-nod-no-diagnostic-needed/. [cited by applicant]
https:www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208447Orig1s000Lbl.pdf. [cited by applicant]
Imai et al., “Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine”, Drug Metab Dispos, vol. 34(10):1734-41, (2006). [cited by applicant]
Isnansetyo et al., “Cytotoxicity of Fucoidan from Three Tropical Brown Algae Against Breast and Colon Cancer Cell Lines,” Pharmacogn J., 2017, 9(1):14-20. [cited by applicant]
Iyevlev et al., “Cytotoxic and targeted therapy for hereditary cancers”, Hereditary Cancer in Clinical Practice, vol. 14:—Aug. 23, 2016. [cited by applicant]
Jaillette et al., “French Intensive Care Society, International congress—Reanimation 2016”, Ann Intensive Care. 2016; 6 (Suppl 1):50. [cited by applicant]
Jdey et al., “Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors”, Clinical Cancer Research, vol. 23 (4): 1001-1011, Feb. 2017. [cited by applicant]
Jenner et al., “Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy”, Future Oncology, vol. 12 (12): 1439-1456, Jun. 2016. [cited by applicant]
Jian et al., “Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage”, Anti-Cancer Drugs, vol. 25 (8): 87… [cited by applicant]
Jones et al., “Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl }-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors,” Journal of Medici… [cited by applicant]
Jones et al., “Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination,” Journal of Medicinal Chemistry, Mar. 11, 2015. [cited by applicant]
Kaeilin, “The concept of synthetic lethality in the context of anticancer therapy”, Nat Rev Cancer, 2005; 5(9): 689-698. [cited by applicant]
Kang et al., “A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy”, J Natl Cancer Inst., 2012; 104(9): 670-681. [cited by applicant]
Kang et al., “Regulation of DNA repair in the absence of classical non-homologous end joining”, DNA Repair, 68: 34-40 (2018). [cited by applicant]
Kanjanapan et al., “Niraparib for the treatment of ovarian cancer”, Expert Opinion on Pharmacotherapy, 18(6): 631-640 (2017). [cited by applicant]
Kaufman et al., “Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation”, Journal of Clinical Oncology, 33(3): 244-250 (2015). [cited by applicant]
Kelley et al., “Targeting DNA repair pathways for cancer treatment: what's new?,” Future Oncol., 2014, 10(7):1215-37. [cited by applicant]
Kim et al., “FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy”, Clin Cancer Res., vol. 21(19), 4257-4… [cited by applicant]
Kim et al., “Molecular Cell Activation of PARP-1 by snoRNAs Controls Ribosome Biogenesis and Cell Growth via the 2 RNA Helicase DDX21” 31 pages, Sep. 19, 2019 © 2019 Elsevier Inc. https://doi.org/10.1016/j.rnolcel.2019.… [cited by applicant]
Konecny et al., “PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions”, British Journal of Cancer, vol. 115 (10): 1157-1173, Nov. 8, 2016. [cited by applicant]
Konstantinophulos et al., “Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma, ” Jama Oncol., 2019, 5(8):1141-49. [cited by applicant]
Konstantinopolous et al., “Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer,” Cancer Discov., Nov. 2015; 5(11):1137-1154. [cited by applicant]
Konstantinopoulos et al., “Dose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer (… [cited by applicant]
Konstantinopoulos et al., “Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer”, J Clin Oncol., 2010; 28(22): 3555-3561. [cited by applicant]
Konstantinopoulos PA et al., “TOPACIO: Preliminary activity and safety in patients with platinum-resistant ovarian cancer in a phase 1/2 study of niraparib in combination with pembrolizumab”, SGO 2018 (ORAL). [cited by applicant]
Konstantinopoulos Pet al., “Phase 1/2 study of niraparib plus pembrolizumab in patients with triple-negative breast cancer or recurrent ovarian cancer (Keynote-162)”, ASCO 2016 (Poster). [cited by applicant]
Kummar et al., “A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas”, Clin Cancer Res., 2012; 18(6): 1726-1734. [cited by applicant]
Kummar et al., “Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer,” AACR Journals, Mar. 31, 2015, 21(7):15… [cited by applicant]
Kuo et al., “Casuarinin from the Bark of Terminalia arjuna Induces Apoptosis and Cell Cycle Arrest in Human Breast Adenocarcinoma MCF-7 Cells,” Planta Med., 2005, 71(3):237-243. [cited by applicant]
Kurman and Shih, “The Origin and Pathogenesis of Epithelial Ovarian Cancer—a Proposed Unifying Theory,” Am. J. Surg. Pathol., Mar. 2010; 34(3): 433-443. [cited by applicant]
Kurzrock R et al., “A phase I study of niraparib in combination with temozolomide (TMZ) in patients with advanced cancer”, ASCO 2014 (Poster). [cited by applicant]
Landen et al., “Early Events in the Pathogenesis of Epithelial Ovarian Cancer,” J. Clin. Oncol., 2008; 26:995-1005. [cited by applicant]
Ledermann al., “Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial)”, BGCS 2017 (Poster, encore publication). [cited by applicant]
Ledermann et al., “eUpdate Ovarian Cancer Treatment Recommendations”, European Society for Oncology (2016). [cited by applicant]
Ledermann et al., “Homologous recombination deficiency and ovarian cancer,” European Journal of Cancer, Apr. 9, 2016, 60:49-58. [cited by applicant]
Ledermann et al., “Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”, Annals of Oncology, 24 (Supplement 6), vi24-vi32 (2013). [cited by applicant]
Ledermann et al., “Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial, ” The Lan… [cited by applicant]
Ledermann, “PARP inhibitors in ovarian cancer”, Annals of Oncology, vol. 27: 40-44 Suppl. Apr. 1, 2016. [cited by applicant]
Lee et al., “Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhi… [cited by applicant]
Lin et al., “Reinventing clinical trials: a review of innovative biomarker trial designs in cancer therapies”, British Medical Bulletin, 114(1):17-27 (2015). [cited by applicant]
Listol et al., “Anxiety and depression symptoms among women attending group-based patient education courses for hereditary breast and ovarian cancer”, Hereditary Cancer in Clinical Practice, 15:2, 1-9 (2017). [cited by applicant]
Liu et al., “New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors”, Current Treatment Options in Oncology, vol. 17 (3):—Mar. 2016. [cited by applicant]
Liu et al., “Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer”, Taiwanese Journal of Obstetrics & Gynecology, vol. 56 (5): 713-714, Oct. 2017. [cited by applicant]
Liu et al., “Targeting tumor suppressor genes for cancer therapy,” Bioessays, Dec. 2015, 37(12):1277-1286. [cited by applicant]
Liu et al., “What is the Place of PARP Inhibitors in Ovarian Cancer Treatment?”, Curr Oncol Rep, 2016, 18:29, 9 pages. [cited by applicant]
Livraghi et al., “PARP inhibitors in the management of breast cancer: current data and future prospects”, BMC Medicine, vol. 13:—Aug. 13, 2015. [cited by applicant]
Lodhia KA et al., “Characterization of 148 Ovarian Cancer tumografls (Avatars) using BROCA-HR deep sequencing”, TAT 2015 (Poster). [cited by applicant]
Longoria et al., “Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer”, Expert Opinion On Drug Metabolism & Toxicology, vol. 14 (5): 543-550, 2018. [cited by applicant]
Lord et al., “Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors”, Annual Review of Medicine, vol. 66: 455-470, 2015. [cited by applicant]
Lord R et al., “Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase 3 trial”, SGO 2018 (Oral). [cited by applicant]
Lynparza® Label Aug. 2017, 25 pages. [cited by applicant]
Lynparza® Label Dec. 2014, 18 pages. [cited by applicant]
Mahipal et al., “Risks and Benefits of Phase 1 Clinical Trial Participation”, Cancer Control, 21 (3): 193-199 (2014). [cited by applicant]
Mahner et al., “ENGOT-OV16/NOVA: Results of secondary efficacy endpoints of niraparib maintenance therapy in ovarian cancer,” Oral Presentation, Presented at SGO 2017, National Harbor, Maryland, Mar. 12-15, 2017, 2 page… [cited by applicant]
Mandrekar et al., “Design of clinical trials for biomarker research in oncology”, Clin. Invest., 1(12): 1627-1636 (2011). [cited by applicant]
Mantovani et al., “The chemokine system in cancer biology and therapy,” Science Direct, Feb. 2010, 21(1):27-39. [cited by applicant]
Markman et al., “Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design”, J Clin Oncol., 2004;22(15):3120-3125. [cited by applicant]
Mateo et al., “A decade of clinical development of PARP inhibitors in perspective”, Annals of Oncology, Jun. 2019, 30:1437-1447. [cited by applicant]
Matulonis et al., “A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial).”, Journal of Clinical Oncology, 2014, 3… [cited by applicant]
Matulonis U et al., “Engot-ov16/nova: A maintenance study with niraparib versus placebo in patients with platinum-sensitive ovarian cancer”, [abstract No. IGCS-0912]. Int J Gynecol Cancer, 2016; 26 (Suppl 3): 19-20; IGC… [cited by applicant]
Matulonis UA et al., “A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial)”, ASCO 2014 (Poster). [cited by applicant]
Matulonis UA et al., “Long Term Benefit of Niraparib Treatment of Recurrent Ovarian Cancer (OC)”, ASCO 2017 (Poster). [cited by applicant]
Matulonis, “Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer”, J Clin Oncol. 2008; 26(35): 57 61-5766. [cited by applicant]
Mazzotta et al., “Nuclear PARP1 expression and its prognostic significance in breast cancer patients”, Tumor Biology, vol. 37 (5): 6143-6153, May 2016. [cited by applicant]
McClachlan et al., “Targeted agents and combinations in ovarian cancer: where are we now?”, Expert Review of Anticancer Therapy, vol. 16 (4): 441-454, Apr. 2, 2016. [cited by applicant]
McGonigle et al., “E7449: A dual inhibitor of PARP1/2 and tankrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling”, Oncotarget, vol. 6 (38): 41307-41323, Dec. 1, 2015. [cited by applicant]
McLachlan et al., “The current status of PARP inhibitors in ovarian cancer”, Tumori, vol. 102 (5): 433-440, Sep-Oct. 2016. [cited by applicant]
Michie CO et al., “Final results of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutatio… [cited by applicant]
Michie et al., “Final Result of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation ca… [cited by applicant]
Mikule et al., “A mouse avatar tumor maintenance study identified a subset of SCLC patient-derived tumor xenograft models sensitive to the PARP inhibitor niraparib”, EORTC-NCI-AACR 2015, 1 page. [cited by applicant]
Mikule et al., “A preclinical evaluation of niraparib efficacy as monotherapy, maintenance and after olaparib treatment (PARP inhibitor after PARP inhibitor) in patient-derived ovarian xenograft tumor models,” Poster, P… [cited by applicant]
Mikule et al., “The PARP inhibitor, niraparib, crosses the blood brain barrier in rodents and is efficacious in a BRCA2-mutant intracranial tumor model,” Poster, Presented at EORTC-NCI-AACR 2015, Boston, Massachusetts, … [cited by applicant]
Mikule, “Targeting Cancers with DNA Repair: Beyond BRCA,” presented at Boston Oncology Drug Discovery Symposium, Oct. 23, 2018, 20 pages. [cited by applicant]
Mills et al., “Homologous Recombination deficiency score shows superior association with outcome compared with its individual score components in platinum-treated serous ovarian cancer,” Presented for the 47th Annual Me… [cited by applicant]
Mirza et al., “A phase 1 study to evaluate the safety and tolerability of bevacizumab-niraparib combination therapy and determine the recommended phase 2 dose (RP2D) in women with platinum-sensitive epithelial ovarian c… [cited by applicant]
Mirza et al., “Efficacy of Niraparib on Progression-free Survival (PFS) in Patients (Pts) with Recurrent Ovarian Cancer (OC) with Partial Response to the Last Platinum-based Chemotherapy,” Poster, Presented at ASCO 2017… [cited by applicant]
Mirza et al., “Engot-OV16/NOVA: A phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum- sensitive ovarian cancer,” Oral Presentation, Presented at I… [cited by applicant]
Mirza et al., “ENGOT-OV16/NSGO/NOVA: A phase 3 randomized double-blind trial of maintenance with parp-inhibitor niraparib vs. placebo in patients with platinum-sensitive ovarian cancer,” Poster, Presented at ESMO 2014, … [cited by applicant]
Mirza et al., “Niraparib alone versus niraparib-bevacizumab combination versus bevacizumab followed by niraparib in women with platinum-sensitive ovarian cancer,” Poster, Presented at ASCO 2015, Chicago, Illinois, May 2… [cited by applicant]
Mirza et al., “Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial),” Oral Presentation, Presented at ESMO 2016, Copenhagen, Denmark, Oct. 7-11, 2016, 2 page… [cited by applicant]
Mirza et al., “Niraparib Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer,” The New England Journal of Medicine, 2016, 375(22):2154-2164. [cited by applicant]
Mirza et al., “Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer”, Supplementary Appendix, N Engl J Med, Dec. 2016, 375(22):2154-2164. [cited by applicant]
Moore al., “Food effect sub study of a phase 3 randomized double-blind trial of maintenance with niraparib, a poly(adp)ribose polymerase (PARP) inhibitor in platinum-sensitive ovarian cancer patients,” Poster, Presented… [cited by applicant]
Moore et al., “Food effect sub study of a phase 3 randomized double-blind trial of maintenance with niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor versus placebo in patients with platinum sensitive ov… [cited by applicant]
Moore et al., “Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer”, N. Eng. J. Med., 1-11 (2018). [cited by applicant]
Moore et al., “Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer”, N. Eng. J. Med., Supplementary Appendix (2018). [cited by applicant]
Moore et al., “Phase 2, open-label study of niraparib in women with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer after 2:3 previous chemotherapy regimens”, ASCO 2… [cited by applicant]
Moore et al., “Safety and efficacy of niraparib in patients with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer (QUADRA)”, [abstract No. IGCS-0883]. Int J Gynecol … [cited by applicant]
Moore et al., “SOLO-1: Phase III trial of maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients with advanced ovarian cancer and a BRCA1/2 mutation”, slides presented at European Society… [cited by applicant]
Moore et al., “The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer”, Cancer Chemother Pharmacol., Mar. 1, 2018; 81 (3):497-5… [cited by applicant]
Moore et al., “The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities”, Gynecologic Oncology, vol. 149 (1): 214-220, Apr. 2018. [cited by applicant]
Morales et al., “Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases,” Critical Reviews in Eukaryotic Gene Expression, 2014, 24(1):15-28. [cited by applicant]
Morgan et al., “PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer”, Cancer Chemotherapy and Pharmacology, vol. 81 (4): 647-658, Apr. 2018. [cited by applicant]
Morin et al., Ovarian Cancer. In: Schwab M. (eds) Encyclopedia of Cancer, Springer, Berlin, Heidelberg. Pages 2671-2674 (2011). [cited by applicant]
Mueller et al., “Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma”, Anticancer Res., Mar. 2013; 33(3):755-62. [cited by applicant]
Mukhopadhy A Y et al., “Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors”, … [cited by applicant]
Mukhopadhyay et al., “Clinicopathological Features of Homologous Recombination-Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival”, Cancer Res, 72: 5675-82, 2012 (Published Onli… [cited by applicant]
Murai J et al., “Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors” Cancer Res., Nov. 1, 2012; 72(21):5588-99. [cited by applicant]
Musella et al., “PARP inhibition: A promising therapeutic target in ovarian cancer”, Cellular and Molecular Biology, vol. 61 (6): 44-61, 2015. [cited by applicant]
Mutch et al., “2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer,” Gynecologic Oncology, 2014, 133(3):401-404. [cited by applicant]
Naipal et al., “PARP inhibitors: the journey from research hypothesis to clinical approval”, Personalized Medicine, vol. 12 (2): 139-154, 2015. [cited by applicant]
National Academies of Sciences, Engineering, and Medicine. “Ovarian cancers: Evolving paradigms in research and care” Washington, DC: The National Academies Press (2016). [cited by applicant]
National Cancer Institute, A Snapshot of Ovarian Cancer, [online] (retrieved on May 19, 2019). Retrieved from the Internet: <https://www.cancer.gov/ty12es/ovarian?redirect=true> and <https://www.cancer.gov/types/ovarian… [cited by applicant]
National Cancer Institute, “Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)-Health Professional Version”, [online] (retrieved on May 19, 2019. Retrieved from the Internet: <https://www… [cited by applicant]
National Cancer Institute, Surveillance, Epidemiology, and End Results Program: Cancer Stat Facts: Ovarian Cancer, [online] (retrieved on May 19, 2019). Retrieved from the Internet <https://seer.cancer.gov/statfacts/htm… [cited by applicant]
Neeser et al., “Budget impact of niraparib as maintenance treatment for Medicare patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based ch… [cited by applicant]
Neeser et al., “The cost consequences of maintenance therapies for patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy”, N… [cited by applicant]
Nikolaides, “PARP inhibitor approved as maintenance for recurrent ovarian cancer”, MDedge Hematology and Oncology, Mar. 27, 2017, retrieved on May 18, 2021, retrieved from URL <“https://www.mdedge.com/hematology-oncolog… [cited by applicant]
Oza A et al., “Quality of live in recurrent ovarian cancer patients treated with niraparib: Results from the ENGOT-OV16/NOVA Trial”, Presented at ESMO; Sep. 8-12, 2017; Madrid, Spain; 9300. [cited by applicant]
Oza et al., “Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective”, Curr Oncol., 2011; 18 Suppl 2:S20-27. [cited by applicant]
Ozols et al., “Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study,” J Clin Oncol., 2003,… [cited by applicant]
Pal et al., “BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases,” Cancer, 2015, 104(12):2807-2816. [cited by applicant]
Parkes et al., “Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes”, Oncologist, vol. 22 (6): 655-666, Jun. 2017. [cited by applicant]
Parpos et al., “Comparison of dose intensity in clinical trial and real world settings for niraparib”, Accepted at ISPOR 2018 (Poster). [cited by applicant]
Pazdur, Richard, Letter from U.S. Department of Health and Human Services, U.S. Food and Drug Administration, NDA 208447, to Charles A. Miller, Vice President, Regulatory Affairs, 1000 Winter Street, Suite 3300, Waltham… [cited by applicant]
PCT International Preliminary Report on Patentability in International Application No. PCT/US2017/040039, dated Jan. 1, 2019, 6 pages. [cited by applicant]
PCT International Preliminary Report on Patentability in International Application No. PCT/US2018/067653, dated Jun. 30, 2020, 11 pages. [cited by applicant]
PCT International Preliminary Report on Patentability in International Application No. PCT/US2020/042065, dated Oct. 20, 2021, 12 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International Application No. PCT/US2017/040039, dated Sep. 22, 2017, 8 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International Application No. PCT/US2018/031876, mailed on Aug. 6, 2018, 14 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International Application No. PCT/US2018/067653, dated May 27, 2019, 18 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International Application No. PCT/US2020/042065, dated Oct. 14, 2020, 10 pages. [cited by applicant]
Pfisterer et al., “Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG,” J Clin Oncol… [cited by applicant]
Pop et al., “Genetic alterations in sporadic triple negative breast cancer,” The Breast, Dec. 5, 2017, 38:30-38. [cited by applicant]
Popov A et al., “Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation”, Cancer Res., 2012; 72(21):5454-5462. [cited by applicant]
Postel-Vinay S et al., “A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer”, Oncogene, Nov. 2, 20131; 32(47):5377-87. [cited by applicant]
Ramus, “The Contribution of BRCA1 and BRCA2 to Ovarian Cancer”, Mol Oncol., 3(2): 138-150 (2009). [cited by applicant]
Reb, “Transforming the death sentence: elements of hope in women with advanced ovarian cancer”, Oncol Nurs Forum, 2007; 34(6): E70-81. [cited by applicant]
Robillard et al., “Abstract 3650: Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 and PD-L1 inhibition in a syngeneic BRCA1 mutant ovarian cancer model,” Cancer Research, Jul. 1, 2017, 77… [cited by applicant]
Rodriguez-Freixinos et al., “Current and emerging treatment options in the management of advanced ovarian cancer”, Expert Opinion On Pharmacotherapy, vol. 17 (8): 1063-1076, 2016. [cited by applicant]
Ross, M. K. et al., “Human carboxylesterases and their role in xenobiotic and endobiotic metabolism”, J Biochem Mol Toxicol, vol. 21(4):187-96, (2007). [cited by applicant]